-transparent.png){kind=logo}
CRH is synthesized in the hypothalamus and released in response to stress into the portal hypophyseal blood; an additional site of synthesis, the placenta, is present only during pregnancy. Placental CRH is released into the maternal and fetal circulation during human pregnancy, and we hypothesized that the chronic fetal stress associated with fetal growth retardation may stimulate placental CRH release. We measured plasma CRH concentrations in the umbilical cord blood of 28 growth-retarded fetuses and 28 normally grown fetuses matched for gestational age and mode of delivery. Plasma ACTH, dehydroepiandrosterone sulfate (DHEAS), and cortisol were also measured in the umbilical cord samples to determine if CRH levels were correlated with levels of pituitary and adrenal hormones. The mean umbilical cord plasma CRH level in the growth-retarded fetuses was 206 +/- 25.8 pmol/L, which was significantly higher than that in the normally grown fetuses matched for gestational age, presence or absence of labor, and mode of delivery (49.4 +/- 16.7 pmol/L; P < 0.01). The mean plasma ACTH level in the growth-retarded fetuses (5.7 +/- 1.2 pmol/L) was significantly higher than that in the normally grown fetuses (3.3 +/- 0.7 pmol/L; P < 0.05). The mean cortisol concentration in the growth-retarded fetuses was 260 +/- 32.5 nmol/L, and that in the normally grown fetuses was 220 +/- 40 nmol/L. The mean DHEAS level was significantly lower in the growth-retarded fetuses (4.8 +/- 0.6 mumol/L) than that in the normally grown fetuses (7.7 +/- 0.6 mumol/L; P < 0.001). There was a significant correlation between umbilical cord plasma CRH and both ACTH and cortisol concentrations as well as a significant negative correlation between CRH and DHEAS levels in the growth-retarded fetuses. The umbilical cord plasma CRH level is extremely elevated in growth-retarded fetuses compared to that in normal fetuses. Placental CRH, like hypothalamic CRH, may be stimulated in conditions of chronic stress and may modulate fetal pituitary-adrenal function in high risk pregnancies.
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 1990,
Journal of perinatal medicine,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
April 1992,
American journal of obstetrics and gynecology,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 1997,
Gynecologic and obstetric investigation,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 1996,
Obstetrics and gynecology,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 2011,
Neuroendocrinology,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
March 1991,
European journal of obstetrics, gynecology, and reproductive biology,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
July 1998,
Obstetrics and gynecology,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 1989,
Endokrynologia Polska,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
January 1986,
Biology of the neonate,
R S Goland, and
S Jozak, and
W B Warren, and
I M Conwell, and
R I Stark, and
P J Tropper
December 1968,
Journal of mental deficiency research,
